Goldline Pharmaceutical (BSE: GLPL) had a P/E of 10.5× on 5 Nov 2026, and the shares are 49% below their 52-week high. It earns ROCE of 39% and ROE of 34%. Debt is 0.64× equity. It is a small-cap company with a market cap of ₹30 Cr; the shares fell 46% over the past year.
- ₹30.88
- ₹30.88
- ₹30.88
- ₹30.88
- 3K
Health check
- ReturnsWeak
−45.6% over the past year.
- Price tagNo peers
P/E 10.5, with no peers to compare.
- Growthn/a
Not enough yearly results to measure.
- ProfitabilityStrong
ROCE 39.3%.
- Balance sheetFair
Debt 0.64× equity, interest covered 3.3×.
- Red flags1 to check
49% below its 52-week high.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹30 Cr
- Small cap
- P/E
- 10.5
- Price to book
- 1.71
- Book value ₹18.03
- Dividend yield
- 0.00%
- ROE
- 33.6%
- Return on equity
- ROCE
- 39.3%
- Return on capital employed
- Debt to equity
- 0.64
- Debt ₹9.16 Cr
- EPS (TTM)
- ₹2.95
- OPM (TTM)
- 29.1%
- Net margin 13.2%
- Sales growth
- n/a
- Year-ago quarter not reported
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 0.95
- EV/EBITDA 4.5
Strengths and risks
Strengths
- Return on equity of 33.6%.
- Return on capital employed of 39.3%.
- Positive operating cash flow in each of the last 3 years.
Risks to check
- 49% below its 52-week high.
About Goldline Pharmaceutical
Goldline Pharmaceutical Limited engages in marketing of pharmaceutical products under the Goldline brand in India. It offers goldline pharma, goldline cardinal, goldline aayushman, goldline inLife, and goldline wellness. The company serves physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, urology, endocrinologists, cardiologists, general physicians, pediatricians, child specialists, neonatologists,…
- Headquarters
- Nagpur
- Employees
- 126
- Sector
- Healthcare
- ISIN
- INE1CLW01015
- Website
- goldlinepharma.in
Price range
- Avg volume (3M)
- 31.1K
- 1-year return
- minus 45.6%
- From 52-week high
- minus 48.5%
Peers
We couldn’t find listed peers for this company.
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- ROE
- 33.6%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| 19.8 | 23.6 | 28.1 | |
| – | +18.7% | +19.1% | |
| 17.4 | 19.2 | 21.9 | |
| 2.4 | 4.3 | 6.1 | |
| 12.2% | 18.4% | 21.9% | |
| −0.1 | −0.1 | −0.1 | |
| 1.5 | 1.5 | 1.8 | |
| 0.2 | 0.2 | 0.3 | |
| −0.2 | −0 | −0.1 | |
| 0.4 | 2.5 | 3.9 | |
| 36.0% | 28.5% | 26.5% | |
| 0.3 | 1.8 | 2.8 | |
| – | +603.8% | +56.9% |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| 3.8 | 4.1 | 8.7 | |
| 2.1 | 3.8 | 1.6 | |
| 10.8 | 11.1 | 11 | |
| 2.7 | 3.9 | 4.9 | |
| 19.4 | 22.9 | 26.3 | |
| 2.5 | 3.4 | 2.8 | |
| – | 0.4 | – | |
| 0 | – | – | |
| 0.1 | 0.8 | 1.2 | |
| 16.8 | 18.3 | 22.2 | |
| 19.4 | 22.9 | 26.3 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| 2.4 | 2.9 | 2.3 | |
| −1 | −1.1 | 0.2 | |
| −1.4 | −1.1 | −2 | |
| −0.1 | 0.7 | 0.4 | |
| −1.1 | −1.1 | −0.2 | |
| 1.3 | 1.8 | 2.1 | |
| −0.2 | −0.2 | −0.2 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.